Celldex Therapeutics, Inc. - FORM 8-K - August 3, 2011
| Attached files | ||||||
| File | Filename | |||||
|---|---|---|---|---|---|---|
| EX-99.1 - EXHIBIT 99.1 - Celldex Therapeutics, Inc. | a6816583ex99_1.htm | |||||
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): August
3, 2011
CELLDEX
THERAPEUTICS, INC.
(Exact
name of registrant as specified in its charter)
|
0-15006 |
||
|
Delaware |
|
13-3191702 |
|
(State or other jurisdiction of incorporation) |
|
(I.R.S. Employer Identification No.) |
|
119 Fourth Avenue |
|
|
|
(Address of principal executive offices) (Zip Code) |
||
(781)
433-0771
(Registrant’s
telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
⃞
Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
⃞
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
⃞
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
⃞
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item 2.02. Results of Operations and Financial Condition.
On August 3, 2011, Celldex Therapeutics, Inc. issued a press release announcing its financial results for the second quarter of 2011. The full text of the press release is furnished as Exhibit 99.1 hereto and is incorporated by reference herein.
The information in this Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
99.1 Press Release of Celldex Therapeutics, Inc., dated August 3, 2011.
[Remainder of page left blank intentionally]
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be filed on its behalf by the undersigned hereunto duly authorized.
|
Celldex Therapeutics, Inc. |
||||||
|
|
||||||
|
Dated: |
August 3, 2011 | By: |
/s/ Avery W. Catlin |
|||
|
Avery W. Catlin |
||||||
|
Senior Vice President and |
||||||
|
Chief Financial Officer |
||||||
Exhibit Index
|
99.1 |
Press Release of Celldex Therapeutics, Inc., dated August 3, 2011. |
User Contributions:
Comment about this document or add new information about this topic:
This web site and associated pages are not associated with, endorsed by, or sponsored by Celldex Therapeutics, Inc. and has no official or unofficial affiliation with Celldex Therapeutics, Inc.
Based on public records. Inadvertent errors are possible.
Faqs.org does not guarantee the accuracy or timeliness of any information on this site. Use at your own risk.
This website is not associated with the SEC
Some parts © 2013 Advameg, Inc.
